Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (431-440 of 744) with videos related to

Pageof 75
Sort By:
Frontiers in Immunology|June 7, 2022
Human Melanoma-Associated Mast Cells Display a Distinct Transcriptional Signature Characterized by an Upregulation of the Complement Component 3 That Correlates With Poor PrognosisRajia Bahri, Orsolya Kiss, Ian Prise, et al.
Oncotarget|October 30, 2016
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistanceMarieke I G Raaijmakers, Daniel S Widmer, Apurva Narechania, et al.
Cancers|January 10, 2026
Neoadjuvant Therapy in Resectable Advanced Melanoma: Swiss Real-World DataAnn-Kathrin Blumenröther, Yongxing Fang, Tamara El Saadany, et al.
Dermatology (Basel, Switzerland)|February 14, 2022
Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeMara Zehnder, Boyko Amarov, André N Abrunhosa-Branquinho, et al.
Nature Communications|March 7, 2013
Aldara activates TLR7-independent immune defenceAnne Walter, Matthias Schäfer, Virginia Cecconi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 16, 2019
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor TreatmentStefan Diem, Mirjam Fässler, David Bomze, et al.
Cancer Immunology, Immunotherapy : CII|September 5, 2019
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patientsBenjamin Weide, Thomas Eigentler, Chiara Catania, et al.
Cancer Immunology Research|July 15, 2020
Activation of CD8<sup>+</sup> T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK InhibitorsJessica L F Teh, Dan A Erkes, Phil F Cheng, et al.
Acta Dermato-Venereologica|November 3, 2015
Expression of CD164 on Malignant T cells in Sézary SyndromeEmmanuella Guenova, Desislava Ignatova, Yun-Tsan Chang, et al.
The New England Journal of Medicine|November 13, 2015
The Genetic Evolution of Melanoma from Precursor LesionsA Hunter Shain, Iwei Yeh, Ivanka Kovalyshyn, et al.
Pageof 75

Showing results (431-440 of 744) with videos related to

Sort By:
Pageof 75
Frontiers in Immunology|June 7, 2022
Human Melanoma-Associated Mast Cells Display a Distinct Transcriptional Signature Characterized by an Upregulation of the Complement Component 3 That Correlates With Poor PrognosisRajia Bahri, Orsolya Kiss, Ian Prise, et al.
Oncotarget|October 30, 2016
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistanceMarieke I G Raaijmakers, Daniel S Widmer, Apurva Narechania, et al.
Cancers|January 10, 2026
Neoadjuvant Therapy in Resectable Advanced Melanoma: Swiss Real-World DataAnn-Kathrin Blumenröther, Yongxing Fang, Tamara El Saadany, et al.
Dermatology (Basel, Switzerland)|February 14, 2022
Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeMara Zehnder, Boyko Amarov, André N Abrunhosa-Branquinho, et al.
Nature Communications|March 7, 2013
Aldara activates TLR7-independent immune defenceAnne Walter, Matthias Schäfer, Virginia Cecconi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 16, 2019
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor TreatmentStefan Diem, Mirjam Fässler, David Bomze, et al.
Cancer Immunology, Immunotherapy : CII|September 5, 2019
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patientsBenjamin Weide, Thomas Eigentler, Chiara Catania, et al.
Cancer Immunology Research|July 15, 2020
Activation of CD8<sup>+</sup> T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK InhibitorsJessica L F Teh, Dan A Erkes, Phil F Cheng, et al.
Acta Dermato-Venereologica|November 3, 2015
Expression of CD164 on Malignant T cells in Sézary SyndromeEmmanuella Guenova, Desislava Ignatova, Yun-Tsan Chang, et al.
The New England Journal of Medicine|November 13, 2015
The Genetic Evolution of Melanoma from Precursor LesionsA Hunter Shain, Iwei Yeh, Ivanka Kovalyshyn, et al.
Pageof 75